Evidence map›Paper›PMID 34232857›Full record

ArticleeLife2021

Genetic and pharmacological evidence for kinetic competition between alternative poly(A) sites in yeast.

Rachael Emily Turner, Paul F Harrison, Angavai Swaminathan, Calvin A Kraupner-Taylor, Belinda J Goldie, Michael See, Amanda L Peterson, Ralf B Schittenhelm, David R Powell, Darren J Creek and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in eLife, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Rachael Emily TurnerDevelopment and Stem Cells Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Melbourne, Australia.ORCID 0000-0001-9319-4825
Paul F HarrisonDevelopment and Stem Cells Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Melbourne, Australia.ORCID 0000-0002-3980-268X
Angavai SwaminathanDevelopment and Stem Cells Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Melbourne, Australia.
Calvin A Kraupner-TaylorDevelopment and Stem Cells Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Melbourne, Australia.
Belinda J GoldieDevelopment and Stem Cells Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Melbourne, Australia.
Michael SeeDevelopment and Stem Cells Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Melbourne, Australia.ORCID 0000-0002-7231-3896
Amanda L PetersonDrug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia.
Ralf B SchittenhelmMonash Proteomics & Metabolomics Facility, Department of Biochemistry and Molecular Biology, Monash Biomedicine Discovery Institute, Monash University, Melbourne, Australia.
David R PowellMonash Bioinformatics Platform, Monash University, Melbourne, Australia.
Darren J CreekDrug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia.
Bernhard DichtlSchool of Life and Environmental Sciences, Deakin University, Geelong, Australia.
Traude H BeilharzDevelopment and Stem Cells Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Melbourne, Australia.ORCID 0000-0002-8942-9502
Monash University · AUDeakin University · AU

Funding

Australian Research Council DP170100569Australian Research Council FT180100049
6 · The paper itself

Abstract

Most eukaryotic mRNAs accommodate alternative sites of poly(A) addition in the 3' untranslated region in order to regulate mRNA function. Here, we present a systematic analysis of 3' end formation factors, which revealed 3'UTR lengthening in response to a loss of the core machinery, whereas a loss of the Sen1 helicase resulted in shorter 3'UTRs. We show that the anti-cancer drug cordycepin, 3' deoxyadenosine, caused nucleotide accumulation and the usage of distal poly(A) sites. Mycophenolic acid, a drug which reduces GTP levels and impairs RNA polymerase II (RNAP II) transcription elongation, promoted the usage of proximal sites and reversed the effects of cordycepin on alternative polyadenylation. Moreover, cordycepin-mediated usage of distal sites was associated with a permissive chromatin template and was suppressed in the presence of an

Indexed as

Polyadenylation3' Untranslated RegionsDNA HelicasesKineticsPoly ARNA HelicasesSaccharomyces cerevisiaeSaccharomyces cerevisiae Proteins3' Untranslated RegionsDNA HelicasesPoly ARNA HelicasesSaccharomyces cerevisiae ProteinsSEN1 protein, S cerevisiaealternative polyadenylationchromosomescleavagecordycepingene expressiongeneticsgenomicsmycophenolic acidpolyadenylationS. cerevisiaeSen1transcription elongation

Identifiers

PMID34232857
PMCPMC8263057
OpenAlexW3182597345

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.